{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:52:30Z","timestamp":1778741550529,"version":"3.51.4"},"reference-count":62,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1116930"],"award-info":[{"award-number":["1116930"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alcohol use disorder (AUD) and methamphetamine use disorder (MUD) are prevalent and have high adverse impacts on both the individual and society. Current treatment strategies for these disorders are ineffective at a population level. Lorcaserin, a 5\u2010HT<jats:sub>2C<\/jats:sub> receptor agonist, has shown potential at reducing the symptoms of substance use disorder. This pilot study (initiated prior to market withdrawal) examined feasibility and safety of lorcaserin treatment in people undergoing residential detoxification and treatment for AUD and MUD. This was an open label pilot study of lorcaserin where participants (<jats:italic>n<\/jats:italic>\u00a0=\u00a010 AUD; <jats:italic>n<\/jats:italic>\u00a0=\u00a08 MUD) received 10\u2010mg lorcaserin daily for 4\u00a0days then twice daily for 1\u00a0month. Primary outcome measures included recruitment and retention rate, incidence of treatment\u2010emergent events, incidence of methamphetamine or alcohol withdrawal\u2010related events, heart rate, and blood pressure. Secondary measures included pharmacokinetic data and self\u2010reported alcohol or methamphetamine use, craving, and psychological distress. AUD participants were recruited faster and had a greater retention rate compared with MUD participants. Lorcaserin did not alter vital signs, was well tolerated, and had a similar pharmacokinetic profile to individuals with obesity. Lorcaserin reduced self\u2010reported alcohol and amphetamine\u2010type substance use and craving in AUD and MUD participants, respectively. Self\u2010reported psychological health also improved over the treatment period for all participants. Despite the pilot nature of this study, our data support the notion of 5\u2010HT<jats:sub>2C<\/jats:sub> receptors as a therapeutic target for drug and alcohol abuse.<\/jats:p>","DOI":"10.1002\/prp2.767","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T10:07:40Z","timestamp":1619777260000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The 5\u2010HT<sub>2C<\/sub> receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment\u2010seeking individuals"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4722-6897","authenticated-orcid":false,"given":"Erin J.","family":"Campbell","sequence":"first","affiliation":[{"name":"Florey Institute of Neuroscience and Mental Health Melbourne Brain Centre The University of Melbourne Parkville VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine St Vincent's Hospital Melbourne The University of Melbourne Parkville VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Pastor","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine St Vincent's Hospital Melbourne The University of Melbourne Parkville VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine St Vincent's Hospital Melbourne The University of Melbourne Parkville VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Norman","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine St Vincent's Hospital Melbourne The University of Melbourne Parkville VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Galettis","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health The University of Newcastle Callaghan NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Johnstone","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health The University of Newcastle Callaghan NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6836-727X","authenticated-orcid":false,"given":"Andrew J.","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Florey Institute of Neuroscience and Mental Health Melbourne Brain Centre The University of Melbourne Parkville VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"World Health Organization.Global status report on alcohol and health.2018."},{"key":"e_1_2_11_3_1","unstructured":"Australian Institute of Health and Welfare.National drug strategy household survey 2016: Detailed findings.2017."},{"key":"e_1_2_11_4_1","unstructured":"National center for health statistics\/centers for disease control; U.S. Department of Justice; Drug Enforcement Administration.National drug threat assessment.2017."},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-4887-7"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-011-2263-y"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.11406"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2019_295"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14755"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn1579"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.110"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(81)90146-9"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1992.72.1.165"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1981.01780330019001"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.15288\/jsa.1988.49.500"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.12.023"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1432.011"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.1370040602"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2010.00145"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1976.tb02783.x"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(95)00138-7"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(99)00086-6"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(99)00011-1"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(01)00710-9"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.09.008"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.09.001"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.20460"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026619666190709101449"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0709034"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.236307"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2014.07.017"},{"key":"e_1_2_11_32_1","unstructured":"Food and drug administration.https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010requests\u2010withdrawal\u2010weight\u2010loss\u2010drug\u2010belviq\u2010belviq\u2010xr\u2010lorcaserin\u2010market. Accessed July 10 2020."},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1989.tb00737.x"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830030047008"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.11.022"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(93)90042-O"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12083"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.01.007"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14748"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.08.016"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1995.tb01475.x"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-842X.2001.tb00310.x"},{"key":"e_1_2_11_44_1","doi-asserted-by":"crossref","first-page":"e12993","DOI":"10.1111\/adb.12993","article-title":"5HT\u20102C agonist lorcaserin decreases cannabis self\u2010administration in daily cannabis smokers","author":"Arout CA","year":"2021","journal-title":"Addict Biol"},{"issue":"8","key":"e_1_2_11_45_1","first-page":"944","article-title":"Lorcaserin for smoking cessation and associated weight gain: a randomized 12\u2010week clinical trial","volume":"19","author":"Shanahan WR","year":"2017","journal-title":"Nicotine Tob Res"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107859"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2019.02.010"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108482"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000209"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.228833"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000234"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.09.025"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108009"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108064"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(200001)35:1<53::AID-SYN7>3.0.CO;2-2"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(98)00078-1"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1884-9"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108307"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01774.x"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2020.02.019"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13249"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2019.21.2\/dnutt"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-0694-z"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.767","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.767","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T06:46:38Z","timestamp":1693205198000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/prp2.767"],"URL":"https:\/\/doi.org\/10.1002\/prp2.767","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"assertion":[{"value":"2021-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00767"}}